GUIDED LECTURE NOTES ADVANCED PHARMACOTHERAPUTICS CENTRAL NERVOUS SYSTEM

LEARNING OUTCOMES

- 1. Review Pathophysiology
- 2. Clinical Pharmacology
- 3. Mechanism of action
- 4. PK/PD
- 5. Medication/Interactions
- 6. ADR's -Adverse drug reactions
- 7. RBA (Risk Benefit Analysis/Stratification)

Medications to include

- Stimulants
- Anticonvulsants

A&P REVIEW


- o CNS
 - o Consists of the brain, spinal cord; Contains most of the nervous system
 - Coordinates the activity of all parts of the body
- The brain and spinal cord serve as the main "processing center" for the entire nervous system and control all the workings of the body.
- o Millions of neurons provide the capacity to reason, experience feelings, and understand the world.
- Neurons provide the capacity to remember numerous pieces of information.

Neurotransmitters (know whether excitatory or inhibitory)

Neurotransmitter	Action and effects
Acetylcholine	
GABA(gamma-aminobutyric acid)	
Glutamate	
Glycine	
Dopamine	
Norepinephrine	
Serotonin	

ANOREXIANTS

- Medications include:
 - Diethylpropion
 - Tenuate, Tenuate Dospan (Category IV)
 - Phendimetrazine tartrate
 - Benzphentamine/Didrex
 - Phentermine (Adepex-P)



- Sibutramine/Meridia (Category IV)
- Important
 - Short-term (8 to 12 weeks) drugs used for weight loss
 - Chemically and pharmacologically related to amphetamines
 - Mode of action
 - stimulate the release of norepinephrine and/or dopamine from storage sites in nerve terminals in the lateral hypothalamic feeding center
 - producing a decrease in appetite

PK/PD

- Lipid-soluble drugs, have wide distribution, cross blood-brain barrier
- Metabolized by liver//excreted by kidneys
- o duration of action 4 to 6 hours
- Have high risk of tolerance and dependence
- o Avoid using with patients with history of alcohol/drug dependence
- o Contraindicated in patients who abuse cocaine, methamphetamine, etc.
- Adverse drug reactions (ADRs)
 - CNS overstimulation:
 - agitation, confusion, insomnia, dizziness, HTN, headache, palpitations, arrhythmias, dry mouth, nausea/vomiting (n/v)
 - Sudden withdrawal of medication
 - in patients w/ long history
 - may cause withdrawal symptoms
 - o Increases glucose uptake from skeletal muscles
 - caution in patients with diabetes
 - Drug interactions
 - Off-label use with selective serotonin reuptake inhibitors (SSRIs)
 - Prozac and phentermine ("Phen-Pro")
 - Careful use with serotonergic medications:
 - increased risk for serotonin syndrome
 - Avoid monoamine oxidase inhibitors (MAOIs):
 - result in hypertensive crisis
 - Careful use with adrenergic blockers, insulin sulfonylureas, and phenothiazines
 - Lithium toxicity

ANTI-SEIZURE MEDICINES

- Typically grouped by their MOA/principal mode of action
 - o Calcium current effectors
 - Ethosuximide, gabapentin and pregabalin
 - Gaba activity
 - Benzodiazepines, phenobarbital, tiagabine, vigabatrin
 - o Glutamate receptor
 - Topiramate, felbamate, perampanel
 - Drugs affecting other MOA
 - Levetiracetam
 - Bind synaptic vesical protein SV2A
- Essentially, ALL antiseizure drugs act by one of these mechanisms:
 - a. Stimulating an influx of chloride ions
 - i. associated with the neurotransmitter gamma-aminobutyric acid (GABA)

- b. Delaying an influx of sodium
- c. Delaying an influx of calcium

ANTICONVULSANTS

- Factors that may precipitate seizures
 - Sleep deprivation, high caffeine intake, hyperventilation, stress, hormonal changes, sensory stimuli, drug/alcohol use, infections, fever, metabolic disorders
- Anticonvulsant medications being used in the treatment of mood disorders


High-voltage Ca channel Phenytoin Carbamazepine Synaptic Valproate vesicle Lamotrigine Pregabalin Felbamate Gabapentin Voltage gated Zonisamide α2δ subunit Voltage gated glutamat Ca channel (L-type) Levetiracetam SV2A Topifamate Kainate NMDA receptor AMPA receptor

Excitatory neurotransmitter system and AEDs

ANTICONVULSANTS: HYDANTOINS

MEDICATIONS IN THIS CLASS

- Ethotoin/Peganone
 - only available in 250 mg
- Fosphenytoin/Cerebyx
 - NOT for primary care
 - IM or IV dosing only
 - Given only for about 5 days
- Phenytoin/Dilantin
 - Nonlinear kinetics, many drugs alter concentration levels
 - Generic vs brand name may have effect on levels



- MOA: act on NA+ channels
- NA+ channels can normally exist in closed, open or inactivated states. AN activated gate is closed and NA+ ions cannot pass through the channel
- The channel activation gate opens, rapidly following depolarization and NA+ enters freely. Soon after opening an inactivation gate close preventing further NA+ getting into the cell.
- Hydantoin drugs stabilize and prolong the existence of the inactivated state and leads to sodium impedance

- PK/PD
 - Pharmacokinetics
 - Metabolism: Liver
 - strong CYP2C9 effects
 - Levels will increase
 - cimetidine, diazepam, acute alcohol intake, valproic acid, allopurinol
 - Decreases effects
 - barbiturates, antacids, calcium, chronic alcohol use
 - Pharmacodynamics
 - Works by stabilizing neuronal membranes and decreasing seizure activity by increasing influx of sodium ions across cell membranes in the motor cortex
 - Onset and duration vary
 - First-line treatment for tonic-clonic and partial complex seizures
 - Depresses neuron transmission in the nucleus ventralis anterior of the thalamus
 - Has ability to induce its own metabolism
 - Genetic testing of Asians

ADRS and DRUG INTERACTIONS

- o Concurrent administration causes the decreased effect of:
 - Carbamazepine
 - Estrogens
 - Acetaminophen
 - Corticosteroids
 - Levodopa
 - sulfonylureas
 - cardiac glycosides
- o Adverse Drug effects
 - there are many
 - ***Never give IV or IM in primary care setting***
 - Watch patients with liver and renal disease closely.
- o Most common ADRs
 - Neuro
 - Nystagmus, dizziness, pruritus, paresthesia, headache, somnolence, ataxia, confusion
 - Cardiovascular effects
 - hypotension, tachycardia
 - Gastrointestinal (GI) effects:
 - n/v, anorexia, constipation, dry mouth, gingival hyperplasia
 - Genitourinary effects:
 - urinary retention, urine discoloration

RATIONAL DRUG SELECTION

- o Nurse practitioner role: working with neurologist who has made diagnosis
- o Used for grand mal and psychomotor seizures

PATIENT EDUCATION: DISCUSS RISK FACTORS FOR SEIZURES

- Report ADR
- Avoid driving if not seizure free for more than 1 year
- Oral hygiene

MONITORING

- Baseline laboratory values and plasma levels, along with thyroid-stimulating hormone (TSH)
- Need to assess OTC drugs: ibuprofen, antacids

ANTICONVULSANTS: CARBAMAZEPINES

Carbamazepine

- o Tegretol, Tegretol XR, Carbatrol
- BLACK BOX WARNING
 - o #1_____
 - o #2_____

- Drug interactions:
 - Watch out for intake with ______
- Drug levels increase
 - o with concurrent use of propoxyphene (Darvocet), cimetidine, erythromycin, clarithromycin, verapamil, hydantoins
- o Decreases plasma levels of several drugs:
 - o beta blockers, warfarin, doxycycline, succinimides, haloperidol
- Oxcarbazepine Trileptal
 - o Chemical structure like carbamazepine
 - Only minimally affects CYP (advantage)
- o ADRs
 - Depression of bone marrow
 - Liver damage, impairs thyroid function
 - o Drowsiness, dizziness, blurred vision, n/v, dry mouth, diplopia, headache (HA)
- Monitoring
 - Baseline laboratory values: complete blood count, chemical panel, hepatic panel, TSH level
 - o Patient education:
 - Teach about symptoms of bone marrow depression, CAREFUL use of medications, therapeutic dosing

ANTICONVULSANTS: SUCCINIMIDES

- o Used for treatment of absence seizures in children and adults
- Ethosuzimide (Zarontin), methsuximide (Celontin)
- o Pharmacodynamics
 - o Suppresses seizures by delaying calcium influx into neurons
 - Decreases nerve impulses and transmission in the motor cortex
 - Absorbed in GI tract
- Pharmacokinetics:
 - o metabolized in liver
- o ADRs
 - o GI most common; CNS: somnolence, fatigue, ataxia
 - Agranulocytosis, aplastic anemia, granulocytopenia

ANTICONVULSANTS: LAMOTRIGINE

- Lamotrigine (Lamictal)
 - Used in the adjunctive treatment of primary generalized tonic-clonic seizures and partial seizures in adults and children older than 2 years of age
 - o Concurrent use with valproic acid, phenytoin
- Pharmacodynamics
 - o Levels decreased by barbiturates, estrogens, phenytoin, mefloquine
 - o Levels increased by alcohol, carbamazepine, CNS depressants, valproic acid
- Pharmacokinetics:
 - o metabolized in liver and kidneys
- o ADRs:
 - GI mostly n/v, constipation; cardiovascular chest pain, peripheral edema; CNS somnolence, fatigue, dizziness, anxiety insomnia, headache, amblyopia, nystagmus; dermatological – rashes

- Patient education
 - o adherence, avoidance of alcohol, avoidance of OTC drugs, adequate hydration, reporting any new drugs, reporting ADRs
 - o Discussion of risk factors that contribute to seizures
 - o Driving
 - o Controversy about discontinuing medications after a few years of being seizure-free: neurologist to make decision

ANTICONVULSANTS: RUFINAMIDE

- o Adjunctive treatment for Lennox-Gestalt syndrome (LGS)
- o Modulates the activity of sodium channels
- o Contraindicated in familial short QT syndrome
- o ADRs: increased suicide risk, DRESS (drug rash with eosinophilia and systemic symptoms)
- o Interactions: carbamazepine, phenobarbital, valproate